MarketCap
Facebook
X
Telegram
Silk Road Medical, Inc Balance Sheet 2023-2011 | SILK
Brief overview of Silk Road Medical, Inc's balance sheet structure
The comparison uses five available annual reports from the 2019–2023 interval.
The asset base grew from $137.4 million to $265.3 million, or +93.1%. Average annual growth of roughly 17.9% was strong.
Growth in the asset base was not matched by liabilities: +93.1% versus +74.3%. The balance sheet moved in a more conservative direction.
The equity ratio reached 57% from 52.3%. A high capital share reduces dependence on liabilities.
Each unit of equity supports about 0.38x of net debt. Dependence on debt remains comfortable.
Cash represents 7.6% of assets versus 28.5% initially, showing how the immediate liquidity reserve changed.
The balance sheet includes a negative accumulated result of -$399.5 million. It should be assessed alongside historical profits and capital distributions.
Balance sheet takeaway
Silk Road Medical, Inc's financial position is positive on balance sheet evidence. Growth in resources has not undermined capital strength.
Annual Balance Sheet Silk Road Medical, Inc
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
57.1 M | 21.1 M | -64.2 M | -20.1 M | 6.47 M | 19.2 M | -5.74 M | - | - | - | - | - | - |
Long Term Debt |
75.6 M | 74.6 M | 44.8 M | 48.5 M | 44.9 M | 44.2 M | 27.6 M | - | - | - | - | - | - |
Long Term Debt Current |
1.7 M | 1.84 M | 1.29 M | 850 K | 769 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 48.6 M | 45.3 M | 137 M | - | - | - | - | - | - |
Total Current Liabilities |
30.3 M | 24.5 M | 26.1 M | 19.6 M | 16.9 M | 10.7 M | - | - | - | - | - | - | - |
Total Liabilities |
114 M | 106 M | 77.4 M | 71.8 M | 65.5 M | 72.1 M | 142 M | - | - | - | - | - | - |
Deferred Revenue |
256 K | 249 K | 157 K | 206 K | 304 K | 137 K | - | - | - | - | - | - | - |
Retained Earnings |
-399 M | -344 M | -289 M | -239 M | -192 M | -139 M | -102 M | - | - | - | - | - | - |
Total Assets |
265 M | 270 M | 157 M | 179 M | 137 M | 42.7 M | 43.1 M | - | - | - | - | - | - |
Cash and Cash Equivalents |
20.2 M | 55.4 M | 110 M | 69.5 M | 39.2 M | 25 M | 33.8 M | - | - | - | - | - | - |
Book Value |
151 M | 164 M | 79.2 M | 108 M | 71.9 M | -29.3 M | -98.6 M | - | - | - | - | - | - |
Total Shareholders Equity |
151 M | 164 M | 79.2 M | 108 M | 71.9 M | -135 M | -98.6 M | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Silk Road Medical, Inc
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
76.1 M | 75.9 M | 75.6 M | 75.4 M | 75.1 M | 74.8 M | 74.6 M | 74.3 M | 74 M | 38.9 M | 44.8 M | 48.7 M | 48.6 M | 48.6 M | 48.5 M | 45.2 M | 45.1 M | 45 M | 44.9 M | 44.8 M | 44.7 M | 44.6 M | 44.2 M | 44.2 M | 44.2 M | 44.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
115 M | 105 M | 114 M | 108 M | 108 M | 102 M | 106 M | 105 M | 103 M | 75.3 M | 77.4 M | 77.4 M | 72.1 M | 68.5 M | 71.8 M | 64.1 M | 60.4 M | 62.8 M | 65.5 M | 61.1 M | 58.3 M | 91.5 M | 72.1 M | 70.2 M | 70.2 M | 70.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
270 K | 317 K | 143 K | 120 K | 220 K | 209 K | 253 K | 298 K | 482 K | 522 K | 157 K | 448 K | 478 K | 536 K | 206 K | 384 K | 335 K | 174 K | 304 K | 335 K | 257 K | 304 K | 137 K | 137 K | 137 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-430 M | -414 M | -399 M | -386 M | -374 M | -360 M | -344 M | -331 M | -321 M | -305 M | -289 M | -274 M | -260 M | -250 M | -239 M | -222 M | -212 M | -201 M | -192 M | -183 M | -175 M | -163 M | -139 M | -139 M | -139 M | -139 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
270 M | 252 M | 265 M | 261 M | 263 M | 260 M | 270 M | 163 M | 163 M | 143 M | 157 M | 166 M | 168 M | 170 M | 179 M | 184 M | 188 M | 127 M | 137 M | 139 M | 143 M | 38.7 M | 42.7 M | 40.9 M | 40.9 M | 40.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
22.6 M | 22.6 M | 20.2 M | 29.2 M | 28.4 M | 50.4 M | 55.4 M | 51.3 M | 87.6 M | 93.6 M | 110 M | 106 M | 102 M | 94.6 M | 69.8 M | 62.5 M | 73.4 M | 27.6 M | 39.2 M | 112 M | 118 M | 15.5 M | 25 M | 25 M | 25 M | 25 M | 33.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
155 M | 147 M | 151 M | 153 M | 156 M | 158 M | 164 M | 57.2 M | 60 M | 67.7 M | 79.2 M | 88.2 M | 96.1 M | 101 M | 108 M | 120 M | 127 M | 64 M | 71.9 M | 77.4 M | 84.4 M | -52.8 M | -29.3 M | -29.3 M | -29.3 M | -29.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
155 M | 147 M | 151 M | 153 M | 156 M | 158 M | 164 M | 57.2 M | 60 M | 67.7 M | 79.2 M | 88.2 M | 96.1 M | 101 M | 108 M | 120 M | 127 M | 64 M | 71.9 M | 77.4 M | 84.4 M | -158 M | -135 M | -135 M | -135 M | -135 M | -98.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Silk Road Medical, Inc, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
France
China
Israel
Britain
Canada
